Drugs Made In America Acquisition (DMAA) Cash & Equivalents (2024 - 2025)

Drugs Made In America Acquisition (DMAA) reported Cash & Equivalents of $6137.0 for Q4 2025, up 354.26% on a YoY basis from $1351.0 in Q4 2024, and up 755.93% quarter-over-quarter from $717.0 in Q3 2025.

Drugs Made In America Acquisition (DMAA) Cash & Equivalents (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition has reported Cash & Equivalents for 2 years, with the latest figure at $6137.0 in Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 354.26% year-over-year to $6137.0; the trailing twelve-month figure through Dec 2025 stood at $6137.0 (up 354.26% YoY), and the FY2025 full-year result was $6137.0, up 354.26% from the prior year.
  • Cash & Equivalents for Q4 2025 stood at $6137.0, up from $717.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $6137.0 in Q4 2025, with the low at $717.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 1.47 Mn
2 Berto Acquisition 312.16 Mn 312.16 Mn - 209,016.00
3 Centurion Acquisition 311.79 Mn 311.79 Mn - 28,828.00
4 Churchill Capital Corp IX 309.64 Mn 309.64 Mn - 167,798.00
5 WEN Acquisition 308.55 Mn 308.55 Mn - 553,972.00
6 Agriculture & Natural Solutions Acquisition 304.08 Mn 304.08 Mn - 1.00
7 Bold Eagle Acquisition 274.25 Mn 274.25 Mn - 521,352.00
8 Soulpower Acquisition 265.17 Mn 265.17 Mn - 56,403.00
9 BTC Development 263.21 Mn 263.21 Mn - 1.45 Mn
10 Drugs Made In America Acquisition 223.11 Mn 223.11 Mn - 6,137.00

Historic Data

Download Data
DateValue
Dec 31, 2025 6,137.00
Sep 30, 2025 717.00
Jun 30, 2025 822.00
Mar 31, 2025 923.00
Dec 31, 2024 1,351.00